The news, announced the first day of this year's TCT (Transcatheter Cardiovascular Therapeutics) conference in Washington, that PercuSurge Inc. , the leader in emboli collection/protection devices, had been purchased by Medtronic Inc. caused some medical device executives to shake their heads in disbelief [See Deal]. Many had viewed a much-anticipated PercuSurge IPO as one of the most promising in the device industry in years, and they were confident that the device itself has the potential to be a blockbuster.
That blockbuster potential, combined with the $225 million price tag, made it seem, frankly, as if PercuSurge had given up too early and too easily. Some executives compared PercuSurge's price...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?